Protein stabilizing factors
Compositions and methods are described for preventing or reducing protein loss due to protein aggregation, denaturation, and adsorption to surfaces. Also described are compositions and methods for preventing or reducing the fouling or clogging of medical devices that come into contact with blood, such as catheters. Also described are methods to treat diseases caused by activation of the microvasculature.
1. A method of reducing or preventing loss of an in vitro protein by adsorption to an in vitro surface or by self-association, wherein the in vitro protein is selected from the group consisting of Von Willebrand Factor (VWF), Factor VIII, ADAMTS13, and Factor IX, the method comprising:
a. exposing the in vitro protein to an amount of Apolipoprotein A1 (ApoA-1), high density lipoprotein (HDL), or ApoA-1 and HDL; and
b. maintaining the in vitro protein in the presence of the amount of ApoA-1, HDL, or ApoA-1 and HDL and thereby reducing or preventing loss of the in vitro protein by adsorption to the in vitro surface or by self-association.
2. The method of claim 1 , wherein the in vitro protein is a recombinant purified protein.
3. The method of claim 1 , wherein the in vitro protein is non-recombinant.
4. The method of claim 1 , wherein the concentration of ApoA-1 is at least 40 μg/mL, and the concentration of HDL is at least 80 μg/mL.
5. The method of claim 1 , wherein the surface is an in vitro medical device surface.
6. The method of claim 1 , wherein the in vitro protein is maintained in the presence of the amount of ApoA-1, HDL, or ApoA-1 and HDL within an in vitro medical device.
7. The method of claim 1 , wherein the method reduces or prevents fouling or clogging of an in vitro medical device.
8. The method of claim 1 , wherein the amount of ApoA-1, HDL, or ApoA-1 and HDL is retained in a transport fluid or a flush solution.
9. The method of claim 6 , wherein the medical device is an in vitro catheter, port, or ventricular assist device.
10. The method of claim 1 , wherein the surface is an in vitro synthetic microvessel surface.
11. The method of claim 5 , wherein the in vitro medical device surface further comprises a coating, and wherein the amount of ApoA-1, HDL, or ApoA-1 and HDL is in the coating.
12. The method of claim 1 , wherein the in vitro protein is VWF.
13. The method of claim 1 , wherein the in vitro protein is Factor VIII.
14. The method of claim 1 , wherein the in vitro protein is ADAMSTS13.
15. The method of claim 1 , wherein the maintaining comprises maintaining the in vitro protein in an amount of ApoA-1 but not HDL.
16. The method of claim 1 , wherein the in vitro protein is human.
17. The method of claim 12 , wherein the VWF is a VWF fragment corresponding to a processed VWF fragment selected from the group consisting of: a proteolytically cleaved VWF fragment, a furin processed VWF fragment, an ADAMTS13 processed VWF fragment, and a thrombospondin-1 processed VWF fragment.
18. The method of claim 12 , wherein the VWF is a VWF fragment corresponding to a A1A2A3 region of VWF.
19. A method of reducing or preventing loss of in vitro Von Willebrand Factor (VWF) by adsorption to an in vitro surface or by self-association, the method comprising:
a. exposing the in vitro VWF to an amount of Apolipoprotein A1 (ApoA-1), high density lipoprotein (HDL), or ApoA-1 and HDL; and
b. maintaining the in vitro VWF in the presence of the amount of ApoA-1, HDL, or ApoA-1 and HDL and thereby reducing or preventing loss of the in vitro VWF by adsorption to the in vitro surface or by self-association.
20. A method of reducing or preventing loss of in vitro Factor VIII by adsorption to an in vitro surface or by self-association, the method comprising:
a. exposing the in vitro Factor VIII to an amount of Apolipoprotein A1 (ApoA-1), high density lipoprotein (HDL), or ApoA-1 and HDL; and
b. maintaining the in vitro Factor VIII in the presence of the amount of ApoA-1, HDL, or ApoA-1 and HDL and thereby reducing or preventing loss of the in vitro Factor VIII by adsorption to the in vitro surface or by self-association.
21. A method of reducing or preventing loss of in vitro ADAMTS13 by adsorption to an in vitro surface or by self-association, the method comprising:
a. exposing the in vitro ADAMTS13 to an amount of Apolipoprotein A1 (ApoA-1), high density lipoprotein (HDL), or ApoA-1 and HDL; and
b. maintaining the in vitro ADAMTS13 in the presence of the amount of ApoA-1, HDL, or ApoA-1 and HDL and thereby reducing or preventing loss of the in vitro ADAMTS13 by adsorption to the in vitro surface or by self-association.
22. A method of reducing or preventing loss of in vitro Factor IX by adsorption to an in vitro surface or by self-association, the method comprising:
a. exposing the in vitro Factor IX to an amount of Apolipoprotein A1 (ApoA-1), high density lipoprotein (HDL), or ApoA-1 and HDL; and
b. maintaining the in vitro Factor IX in the presence of the amount of ApoA-1, HDL, or ApoA-1 and HDL and thereby reducing or preventing loss of the in vitro Factor IX by adsorption to the in vitro surface or by self-association.
23. The method of claim 1 , wherein the in vitro protein is Factor IX.
24. The method of claim 1 , wherein the method comprises reducing or preventing loss of the in vitro protein by adsorption to the in vitro surface.
25. The method of claim 1 , wherein the method comprises reducing or preventing loss of the in vitro protein by self-association.